DENOSUMAB: A NEW ERA IN OSTEOPOROSIS MANAGEMENT IN VIETNAM

Van Tuan, N; Pham Thuc Lan, H

DENOSUMAB: A NEW ERA IN OSTEOPOROSIS MANAGEMENT IN VIETNAM

Van Tuan, N Pham Thuc Lan, H

Permalink

Publisher:: Thong Nhat Hospital
Publication Type:: Journal Article
Citation:: Tạp chí Sức khỏe và Lão hóa, 1, (5), pp. 4-10

Open Access

Copyright Clearance Process

Recently Added
In Progress
Open Access

This item is open access.

Adobe PDF

Download Published versionAdobe PDF (258.54 kB)

View on publisher's site

View statistics

Full metadata record

Field	Value	Language
dc.contributor.author	Van Tuan, N
dc.contributor.author	Pham Thuc Lan, H
dc.date.accessioned	2026-05-26T02:20:21Z
dc.date.available	2026-05-26T02:20:21Z
dc.identifier.citation	Tạp chí Sức khỏe và Lão hóa, 1, (5), pp. 4-10
dc.identifier.issn	3093-3080
dc.identifier.issn	3093-3099
dc.identifier.uri	http://hdl.handle.net/10453/195126
dc.description.abstract	Osteoporosis is a skeletal disorder characterized by compromised bone strength and increased fracture risk. In Vietnam, the disease affects 30 in postmenopausal women and 10 in men over 50, highlighting a growing public health challenge as the population ages. Bisphosphonates remain the standard firstline treatment. Recent advances in bone biology highlight the critical role of the RANK/RANKL/OPG pathway in bone remodeling. Osteoporosis arises when the RANKL/OPG ratio becomes imbalanced. Denosumab, a monoclonal antibody that targets RANKL, replicates OPG s ability to suppress osteoclast activity, increasing bone mineral density and reducing fracture risk by 20 68 across various skeletal sites. Unlike bisphosphonates, Denosumab is reversible, metabolized by the reticuloendothelial system, and appropriate for patients with advanced kidney disease, though it necessitates monitoring for hypocalcemia. This advancement offers clinicians a valuable tool for managing osteoporosis in Vietnam.
dc.language	en
dc.publisher	Thong Nhat Hospital
dc.relation.ispartof	Tạp chí Sức khỏe và Lão hóa
dc.relation.isbasedon	10.63947/bvtn.v1i5.2
dc.rights	info:eu-repo/semantics/openAccess
dc.title	DENOSUMAB: A NEW ERA IN OSTEOPOROSIS MANAGEMENT IN VIETNAM
dc.type	Journal Article
utslib.citation.volume	1
pubs.organisational-group	University of Technology Sydney
pubs.organisational-group	University of Technology Sydney/Faculty of Engineering and Information Technology
pubs.organisational-group	University of Technology Sydney/Faculty of Engineering and Information Technology/School of Biomedical Engineering
pubs.organisational-group	University of Technology Sydney/UTS Groups
pubs.organisational-group	University of Technology Sydney/UTS Groups/UTS Ageing Research Collaborative (UARC)
pubs.organisational-group	University of Technology Sydney/UTS Groups/INSIGHT: Institute for Innovative Solutions for Wellbeing and Health
pubs.organisational-group	University of Technology Sydney/UTS Groups/Centre for Health Technologies (CHT)
utslib.copyright.status	open_access	*
pubs.consider-herdc	true
dc.rights.license	This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0). To view a copy of this license, visit https://creativecommons.org/licenses/by-nc-nd/4.0/
dc.date.updated	2026-05-26T02:20:19Z
pubs.issue	5
pubs.publication-status	Published
pubs.volume	1
utslib.citation.issue	5

Abstract:

Osteoporosis is a skeletal disorder characterized by compromised bone strength and increased fracture risk. In Vietnam, the disease affects 30 in postmenopausal women and 10 in men over 50, highlighting a growing public health challenge as the population ages. Bisphosphonates remain the standard firstline treatment. Recent advances in bone biology highlight the critical role of the RANK/RANKL/OPG pathway in bone remodeling. Osteoporosis arises when the RANKL/OPG ratio becomes imbalanced. Denosumab, a monoclonal antibody that targets RANKL, replicates OPG s ability to suppress osteoclast activity, increasing bone mineral density and reducing fracture risk by 20 68 across various skeletal sites. Unlike bisphosphonates, Denosumab is reversible, metabolized by the reticuloendothelial system, and appropriate for patients with advanced kidney disease, though it necessitates monitoring for hypocalcemia. This advancement offers clinicians a valuable tool for managing osteoporosis in Vietnam.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/195126